The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma
Keywords:
Prostatic neoplasms, Genes, Tumor suppressor genes, Oncogenes, Genes, p53, Proliferating cell nuclear antigen, Receptor erbBAbstract
CONTEXT: Prostate cancer is the most frequent solid genitourinary neoplasm in men. Involvement of several genes has been described in the promotion and progression of prostate carcinoma. OBJECTIVE: To study the expression of the oncogenes HER2/neu and BCL2, tumor suppressor gene p53 and the tumor proliferation rate in 150 radical prostatectomy specimens, in order to define their role as prognostic parameters in localized prostate cancer. TYPE OF STUDY: Prospective study. SETTING: Universidade Federal de São Paulo and Hospital Sírio Libanês, Sao Paulo PARTICIPANTS: One hundred and fifty men who were submitted to radical prostatectomy between August 1997 and August 1998, for localized prostate cancer. MAIN MEASUREMENTS: All specimens underwent evaluation in their entirety, to determine tumor volume percentage, tumor extent and Gleason score. Immunohistochemistry was performed to determine gene expression using anti- HER2/ neu, BCL2 and p53 antibodies, and proliferating cell nuclear antigen. The chi-squared test was used for correlation between gene expression, proliferative activity and histological variables. RESULTS: Thirty percent of the cases were p53 positive. There was positive correlation between p53 expression and tumor stage. The p53 expression was 22.9% and 42.6% for pT2 and pT3 tumors, respectively (p = 0.01). Expression of HER2/neu, BCL2 and proliferating cell nuclear antigen was identified in 66%, 23% and 43% of patients, respectively. There was no correlation between these three parameters and tumor volume, Gleason score or tumor stage. CONCLUSION: One-third of prostate adenocarcinomas express p53 protein, and this characteristic is related to tumor stage. HER2/neu is frequently expressed in prostate carcinomas, with no correlation with histological parameters. BCL2 is rarely expressed, and together with proliferative activity has no relationship with prognostic pathological variables in these neoplasms.
Downloads
References
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53(1):5-26
Grönberg H, Xu J, Smith JR, et al. Early age at diagnosis in families providing evidence of linkage to the hereditary pros- tate cancer locus (HPC1) on chromosome 1. Cancer Res. 1997;57(21):4707-9.
Brasil. Ministério da Saúde. Instituto Nacional do Câncer. Estimativas de incidência e mortalidade por câncer no Brasil 2003. Available from URL: http://www.inca.gov.br/estimativas/ 2003/Accessed in 2004 (Apr 30).
Padhy LC, Shih C, Cowing D, Finkelstein R, Weinberg RA. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell. 1982; 28(4):865-71.
Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in hu- man prostatic carcinoma. J Urol. 1993;150(5 Pt 1):1427-33.
Gu K, Mes-Masson AM, Gauthier J, Saad F. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett. 1996;99(2):185-9.
Visakorpi T. New pieces to the prostate cancer puzzle. Nat Med. 1999;5(3):264-5.
McDonnell TJ, Navone NM, Troncoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone mar- row metastases of androgen independent prostate cancer. J Urol. 1997;157(2):569-74.
Sinha BK, Yamazaki H, Eliot HM, Schneider E, Borner MM, O’Connor PM. Relationships between proto-oncogene expres- sion and apoptosis induced by anticancer drugs in human pros- tate tumor cells. Biochim Biophys Acta. 1995;1270(1):12-8.
Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene. 1992;7(4):743-9.
Navone NM, Troncoso P, Pisters LL, et al. p53 protein accu- mulation and gene mutation in the progression of human pros- tate carcinoma. J Natl Cancer Inst. 1993;85(20):1657-69.
Quinn DI, Henshall SM, Head DR, et al. Prognostic signifi- cance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res. 2000;60(6):1585-94.
Leite KR, Franco MF, Srougi M, et al. Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol. 2001;14(5):428- 36.
Hofstädter F, Knüchel R, Rüschoff J. Cell proliferation assess- ment in oncology. Virchows Arch. 1995;427(3):323-41.
Leite KR, Srougi M, Nesralhah LJ, Camara-Lopes LH. Analy- sis of p53 expression and proliferative assessment using PCNA in localized prostate carcinoma. Braz J Med Biol Res. 1999;32(3):283-8.
Visakorpi T. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) im- munohistochemistry as a prognostic factor in prostatic carci- noma. J Pathol. 1992;168(1):7-13.
Gleason DF. The Veterans Administration Cooperative Urological Research Group: Histologic grading and clinical stat- ing of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia: Lea and Febiger; 1977. p.171-97.
Humphrey PA, Vollmer RT. Intraglandular tumor extent and prognosis in prostatic carcinoma: application of a grid method to prostatectomy specimens. Hum Pathol. 1990;21(8):799-804.
Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate Suppl. 1992;4:129-38.
Cattoretti G, Suurmeijer AJH. Antigen unmasking on forma- lin-fixed paraffin-embedded tissues using microwaves: a review. Adv Anat Pathol. 1995;2(1):2-9.
Taylor CR, Cote RJ. Immunocytomicroscopy: a diagnostic tool for surgical pathologist. In: Major Problems in Pathology, Vol 19, 2nd Edition. Philadelphia,: WB Saunders Company; 1994. p.421-3.
Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with pros- tate cancer. JAMA. 1999;281(15):1395-400
Pan CC, Potter SR, Partin AW, Epstein JI. The prognostic sig- nificance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol. 2000;24(4):563-9.
Norberg M, Holmberg L, Wheeler T, Magnusson A. Five year follow-up after radical prostatectomy for localized prostate cancer - a study of the impact of different tumor variables on pro- gression. Scand J Urol Nephrol. 1994;28(4):391-9.
Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic car- cinomas defined by p53 accumulation. J Natl Cancer Inst. 1992;84(11):883-7.
Cheng L, Leibovich BC, Bergstralh EJ, et al. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression? Cancer. 1999;85(11):2455-9.
Matsushima H, Kitamura T, Goto T, Hosaka Y, Homma Y, Kawabe K. Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carci- noma. J Urol. 1997;158(6):2278-83.
Thomson TA, Hayes MM, Spinelli JJ, et al. HER-2/neu in breast cancer: interobserver variability and performance of immuno- histochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol. 2001;14(11):1079-86.
Mellon K, Thompson S, Charlton RG, et al. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malig- nant prostate. J Urol. 1992;147(2):496-9.
Mydlo JH, Kral JG, Volpe M, Axotis C, Macchia RJ, Pertschuk LP. An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate can- cer preliminary results and therapeutic implications. Eur Urol. 1998;34(5):426-32.
McDonnell TJ, Navone NM, Troncoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone mar- row metastases of androgen independent prostate cancer. J Urol. 1997;157(2):569-74.
Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are inde- pendent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol. 1998;110(4):443-9.
Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. p53, bcl-2 and retinoblastoma proteins as long-term prognos- tic markers in localized carcinoma of the prostate. J Urol. 1997;158(1):131-7.
Moul JW. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol. 1999;35(5-6):399-407.
